Translational Development Acquisition reported cash from operations of -$0.34M and free cash flow of -$0.34M for the quarter ended Jun 2026, down 97.7% year over year. This cash flow statement covers 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -0.06M | -0.13M | -0.35M | -0.22M | -0.21M | -0.16M | -0.28M | -0.66M |
| Cash from OperationsCash from Ops. | -0.81M | -0.23M | -0.17M | -0.09M | -0.12M | -0.31M | -0.34M | |
| Change in Working Capital | ||||||||
| Change in Accured ExpensesChange Accured Exp. | 0.02M | -0.47M | 0.09M | -0.06M | 0.01M | -0.01M | -0.01M | 0.26M |
| Financing Activities | ||||||||
| Cash from Financing ActivitiesCash from Financing | 0.19M | 175.25M | 0.10M | 0.30M | -27.22M | |||
| Additional items | ||||||||
| Change in Cash | 0.15M | 0.21M | -0.23M | -0.17M | 0.01M | -0.02M | -0.01M | 0.06M |
| Free Cash FlowFCF | -0.81M | -0.23M | -0.17M | -0.09M | -0.12M | -0.31M | -0.34M | |
| Net Cash FlowNCF | 0.19M | 174.44M | -0.23M | -0.17M | -0.09M | -0.02M | -0.01M | -27.56M |